Total amount raised
$207 Millions
Latest funding date
01/01/2025
Location
Atalanta Therapeutics has successfully raised $97 million in its latest Series B financing round, aimed at advancing RNA interference therapies for central nervous system diseases. The company is backed by a total of nine investors, including RiverVest and GHR Foundation.
Keep reading to explore the intricacies of Atalanta Therapeutics' fundraising journey and the investors supporting this innovative biotechnology company.
What Is Atalanta Therapeutics?
Atalanta Therapeutics, founded in 2018, is a biotechnology company based in Boston, Massachusetts. The company focuses on developing innovative treatments for neurodegenerative diseases using its proprietary RNA interference platform.
Founded by Anastasia Khvorova, Craig Mello, Jim Glasheen, and Neil Aronin, Atalanta Therapeutics is a women-founded and women-led organization. The company employs between 51 and 100 people and has raised significant funding through a Series B round.
How Much Funding Has Atalanta Therapeutics Raised?
- Series A
- Amount Raised: $110 million
- Date: January 2021
- Lead Investors: F-Prime Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance branched siRNA technology for treating neurodegenerative diseases and support strategic collaborations with Biogen and Genentech.
- Series B
- Amount Raised: $97 million
- Date: January 2025
- Lead Investors: RiverVest and GHR Foundation
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing research and development efforts in pioneering new treatment options for neurodegenerative diseases.
Total Amount Raised: $207 million. Current Valuation: Not publicly disclosed.
Key Investors
- EQT Life Sciences
- Details: EQT Life Sciences is a prominent investment firm specializing in life sciences. They focus on supporting companies that are developing innovative healthcare solutions.
- Investment Focus Areas: Biotechnology, pharmaceuticals, medical devices.
- Notable Investments: Not publicly disclosed.
- Sanofi Ventures
- Details: Sanofi Ventures is the corporate venture capital arm of Sanofi, a global healthcare leader. They invest in early-stage companies with the potential to transform healthcare.
- Investment Focus Areas: Biotechnology, digital health, medical devices.
- Notable Investments: Not publicly disclosed.
- F-Prime Capital
- Details: F-Prime Capital is a venture capital firm that provided the $110 million Series A funding for Atalanta Therapeutics. The firm is represented on Atalanta’s Board of Directors by Stephen Knight, M.D., MBA, Stacie Weninger, Ph.D., and Jessica Alston, Ph.D.
- Investment Focus Areas: Biotechnology, healthcare, medical technologies.
- Notable Investments: Not publicly disclosed.
What's Next for Atalanta Therapeutics?
Atalanta Therapeutics stands at the cusp of significant opportunities, driven by its pioneering RNA interference platform. With strategic collaborations with Biogen and Genentech, the company is poised to develop groundbreaking treatments for neurodegenerative diseases like Huntington’s, Parkinson’s, and Alzheimer’s. These partnerships not only promise substantial milestone payments and royalties but also position Atalanta as a key player in the biotech industry.
Given the successful Series A funding of $110 million, future fundraising rounds seem promising. The biotech sector's growing interest in RNAi therapeutics and neurodegenerative disease treatments suggests that Atalanta could attract further investments, potentially leading to acquisitions by larger pharmaceutical companies.
However, the path forward is not without challenges. Atalanta must navigate scientific and clinical hurdles, regulatory approvals, and competition from other biotech firms. The success of their strategic collaborations will be crucial in overcoming these obstacles and achieving their ambitious goals.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Atalanta Therapeutics and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
